GenSight Biologics
SIGHT.PA
#10724
Rank
A$31.64 M
Marketcap
A$0.13
Share price
3.20%
Change (1 day)
-29.75%
Change (1 year)

P/E ratio for GenSight Biologics (SIGHT.PA)

P/E ratio at the end of 2025: -1.20

According to GenSight Biologics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.92518. At the end of 2025 the company had a P/E ratio of -1.20.

P/E ratio history for GenSight Biologics from 2016 to 2025

PE ratio at the end of each year

Year P/E ratio Change
2025-1.20-38.22%
2024-1.94125.3%
2023-0.8608-85.25%
2022-5.84-34.84%
2021-8.9637.83%
2020-6.50185.82%
2019-2.27-9.9%
2018-2.52-51.76%
2017-5.23-13.57%
2016-6.05

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.